Post by Novotech

It’s Day 2 of BIO 2026, and one thing Dr. Judith Ng-Cashin, M.D., Chief Medical Officer at Novotech is hearing repeatedly in conversations with sponsors is the pressure to demonstrate efficacy earlier. As biotech companies look to make every development dollar count, many are exploring global development pathways, starting first-in-human studies in Australia, accelerating enrollment in China, and then returning to the US and Europe for pivotal trials. Hear her perspective on this growing trend. #BIO2026 #Biotech #DrugDevelopment #ClinicalTrials

Video Content